Literature DB >> 10419879

Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C.

A Zivelin1, S Gitel, J H Griffin, X Xu, J A Fernandez, U Martinowitz, Y Cohen, H Halkin, U Seligsohn, A Inbal.   

Abstract

Activated protein C resistance (APCR) in the absence of alterations in the factor V gene has been observed during pregnancy, in patients on oral contraceptives, in the presence of antiphospholipid antibodies, and in patients with ischemic stroke. We report a 49-year-old woman with recurrent major venous and arterial thromboses who displayed pronounced APCR, yet no changes in the activated protein C (APC) cleavage sites of factor V. The APCR values determined by four different assays were similar to those obtained in plasma from a homozygote for factor V Q506. Addition of IgG isolated from the patient's serum to normal plasma lowered the APCR ratio from 2.4 to 1.6. Incubation of patient's IgG with normal APC resulted in a profound change in the mobility of APC in crossed immunoelectrophoresis. APC was also shown to bind to patient's IgG immobilized on a protein A agarose column. Factor Va inactivation by APC was inhibited by patient's IgG, but not by control IgG in the presence or absence of either phospholipids or protein S. These results provide evidence for the existence of an acquired antibody against APC in the patient's plasma, which gave rise to the APCR phenotype and was probably responsible for the major thrombotic events. We suggest that acquired APCR due to anti-APC antibodies be considered a potential cause for severe venous and arterial thromboses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419879

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature.

Authors:  B Kovacs; T L Lafferty; L H Brent; R J DeHoratius
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

2.  A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C.

Authors:  Kwan-Ki Hwang; Cheng-De Yang; Weihong Yan; Jennifer M Grossman; Bevra H Hahn; Pojen P Chen
Journal:  Arthritis Rheum       Date:  2003-06

3.  Drotrecogin alfa (activated).

Authors:  Katherine A Lyseng-Williamson; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Acquired activated protein C resistance and thrombosis in multiple myeloma patients.

Authors:  Víctor Hugo Jiménez-Zepeda; Virginia Jeanet Domínguez-Martínez
Journal:  Thromb J       Date:  2006-08-21

5.  Comparative response of platelet fV and plasma fV to activated protein C and relevance to a model of acute traumatic coagulopathy.

Authors:  James E Campbell; Michael Adam Meledeo; Andrew P Cap
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

6.  Pathogenesis of Antiphospholipid Syndrome.

Authors:  Borut Bo Ic
Journal:  EJIFCC       Date:  2004-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.